NCT04252846 is a clinical trial of Perampanel in Idiopathic Generalized Epilepsy, sponsored by Eisai Limited.

Who is sponsoring NCT04252846?

NCT04252846 is sponsored by Eisai Limited.

What drugs are being tested in NCT04252846?

Interventions in NCT04252846: Perampanel.

What condition does NCT04252846 study?

NCT04252846 studies Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures.

Is NCT04252846 still recruiting?

NCT04252846 is currently completed. Last updated 9 February 2023.

Last reviewed 2023-02-09 · How we verify

NCT04252846

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Completed Last updated 9 February 2023

What this trial tests

trial testing Perampanel in Idiopathic Generalized Epilepsy in 191 participants. Completed in 12 January 2023.

Timeline

20 July 2020

Primary endpoint
12 January 2023

12 January 2023

Quick facts

Lead sponsor	Eisai Limited
Status	Completed
Study type	OBSERVATIONAL
Enrollment	191
Start date	20 July 2020
Primary completion	12 January 2023
Estimated completion	12 January 2023
Sites	36 locations across Denmark, France, Italy, Russia, Germany, Portugal, Spain

Drugs / interventions tested

Perampanel (PERAMPANEL) — full drug profile →

Conditions studied

Idiopathic Generalized Epilepsy — all drugs for Idiopathic Generalized Epilepsy →
Partial Onset Seizures — all drugs for Partial Onset Seizures →
Generalised Tonic-Clonic Seizures — all drugs for Generalised Tonic-Clonic Seizures →

Sponsor

Eisai Limited — full company profile →

Who can join

12 and older, any sex, with Idiopathic Generalized Epilepsy or Partial Onset Seizures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures \[POS\] with or without secondary generalization \[SG\] or for primary generalized tonic-clonic seizures \[PGTCS\] associated with idiopathic generalized epilepsy \[IGE\] as first adjunctive to antiepileptic drug (AED) monotherapy as part of their routine clinical care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Phase 4, multicenter, prospective, non-interventional, observational study to investigate the effectiveness and safety/tolerability of perampanel when used as first adjunctive therapy in routine clinical practice in people with epilepsy: Study 512.
Burd S, Assenza G, Quintas S, Gil López FJ, et al · · 2025 · PMID 40303887 · DOI 10.3389/fneur.2025.1533767

Verify or expand the search:

Other trials of Perampanel

Trials testing the same drug.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
NCT04309721 — Perampanel in Focal Status Epilepticus · Phase 3 · terminated
NCT05533814 — A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizure · Phase 4 · completed

Other Eisai Limited trials

Trials by the same sponsor.

NCT06043700 — A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology · active not recruiting
NCT05607537 — A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-1 · Phase 1 · completed
NCT04840927 — A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets · Phase 1 · withdrawn
NCT04493255 — A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants · Phase 1 · completed
NCT04257604 — A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04252846 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Limited
Last refreshed: 9 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04252846.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing